I'm not from the UK haven't been involved in any preparation for the final NICE guideline release but I do hope that UK patient organizations are preparing for the ensuing debate in the media.
I hope they are contacting scientists like Brian Hughes, David Tuller, Jonathan Edwards, Caroline Wilshire, and others to prepare comments on the guideline in advance.
I also hope that people are working on that already. Anyway, these are some questions that I likely would have asked if I were a journalist or an other observer new to the topic:
1) Was the evaluation of the benefits of treatment options done equally sound as before and as it is done with other guidelines?
2) How can it be explained that systematic reviews on the benefits of similar treatments for fatigue associated with other illnesses suggest they are effective?
3) In which way did patients influence the assessment of the quality of evidence?
4) Which role did the potential harm of treatment options in the evaluation of the evidence base play?[*]
I'm sorry that I am not able to work on substantiating accurate and short answers to these questions.
From following the process on the forum I'm sure though that the accurate answers will leave no doubt that both with regard to a scientific approach and to patient involvement, the review process of the new guideline was done properly, and probably even better than in the development of most other guidelines.
In addition, even though the simplest answer on question 2) seems to be that ME/CFS is a distinct illness and there is no evidence that fatigue e.g. in MS, RA or Cancer is similar to symptoms experienced by pwME -- maybe there is something that could be learned from the update on this NICE guideline about the difficulties of assessing the evidence delivered by clinical trials on non-pharmacological treatments in general.
[*] I think the point about potential harms could include a short explanation on or reference to why, generally, the evidence of harm is evaluated with different criteria than the evaluation of benefits. In addition, there is the issue with an apparent lack of ensuring the report of harms from non-pharmacological treatments, see:
Struthers, C., It is not only drugs and devices that can harm, HealthWatchUK, 2021,
https://www.healthwatch-uk.org/publications/newsletter/newsletter-114/221-114-cbt-get.html